AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 162 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,821,155 | -12.6% | 73,582 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $2,083,842 | +23.3% | 73,582 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $1,690,179 | -18.2% | 73,582 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $2,066,183 | -0.7% | 73,582 | +0.0% | 0.00% | 0.0% |
Q3 2022 | $2,080,000 | +27.5% | 73,560 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $1,631,000 | -23.8% | 73,560 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $2,141,000 | -11.2% | 73,560 | +0.3% | 0.00% | 0.0% |
Q4 2021 | $2,411,000 | -28.8% | 73,360 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $3,386,000 | -16.9% | 73,360 | -0.8% | 0.00% | -50.0% |
Q2 2021 | $4,076,000 | +149.4% | 73,960 | +133.7% | 0.00% | +100.0% |
Q1 2021 | $1,634,000 | -43.8% | 31,642 | -52.8% | 0.00% | 0.0% |
Q4 2020 | $2,905,000 | -26.6% | 67,042 | -40.7% | 0.00% | -50.0% |
Q3 2020 | $3,958,000 | -10.5% | 113,094 | +36.9% | 0.00% | -33.3% |
Q2 2020 | $4,420,000 | +31.6% | 82,640 | -12.7% | 0.00% | +50.0% |
Q1 2020 | $3,358,000 | +157.7% | 94,652 | +246.8% | 0.00% | +100.0% |
Q4 2019 | $1,303,000 | -72.2% | 27,292 | -81.1% | 0.00% | -66.7% |
Q3 2019 | $4,682,000 | +283.1% | 144,492 | +490.0% | 0.00% | +200.0% |
Q2 2019 | $1,222,000 | -58.0% | 24,492 | -43.2% | 0.00% | -50.0% |
Q1 2019 | $2,907,000 | +166.5% | 43,112 | +82.2% | 0.00% | +100.0% |
Q4 2018 | $1,091,000 | -41.4% | 23,662 | -2.1% | 0.00% | 0.0% |
Q3 2018 | $1,863,000 | -10.3% | 24,162 | -2.1% | 0.00% | 0.0% |
Q2 2018 | $2,078,000 | +9.4% | 24,672 | +6.2% | 0.00% | 0.0% |
Q1 2018 | $1,899,000 | +53.5% | 23,222 | +7.3% | 0.00% | 0.0% |
Q4 2017 | $1,237,000 | -45.2% | 21,642 | -36.0% | 0.00% | -50.0% |
Q3 2017 | $2,256,000 | +101.6% | 33,792 | +55.4% | 0.00% | +100.0% |
Q2 2017 | $1,119,000 | +2.5% | 21,742 | +16.3% | 0.00% | 0.0% |
Q1 2017 | $1,092,000 | +40.0% | 18,692 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $780,000 | -18.2% | 18,692 | +3.6% | 0.00% | 0.0% |
Q3 2016 | $953,000 | +26.1% | 18,050 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $756,000 | +109.4% | 18,050 | +102.8% | 0.00% | – |
Q1 2016 | $361,000 | -38.6% | 8,900 | -1.8% | 0.00% | -100.0% |
Q4 2015 | $588,000 | -97.4% | 9,060 | -97.2% | 0.00% | -95.0% |
Q3 2015 | $22,972,000 | -37.0% | 325,434 | -0.8% | 0.02% | -33.3% |
Q2 2015 | $36,456,000 | +13.8% | 328,022 | -3.4% | 0.03% | +15.4% |
Q1 2015 | $32,027,000 | +13.3% | 339,625 | +34.7% | 0.03% | +13.0% |
Q4 2014 | $28,258,000 | +1885.8% | 252,214 | +987.1% | 0.02% | +2200.0% |
Q3 2014 | $1,423,000 | -0.5% | 23,200 | -25.6% | 0.00% | 0.0% |
Q2 2014 | $1,430,000 | +1374.2% | 31,200 | +1163.2% | 0.00% | – |
Q1 2014 | $97,000 | -27.1% | 2,470 | -55.7% | 0.00% | – |
Q4 2013 | $133,000 | +6550.0% | 5,570 | +7857.1% | 0.00% | – |
Q3 2013 | $2,000 | – | 70 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BB BIOTECH AG | 2,719,998 | $155,502,000 | 4.38% |
Casdin Capital, LLC | 295,000 | $16,865,000 | 4.11% |
Opaleye Management Inc. | 130,000 | $7,432,000 | 2.38% |
Opus Point Partners Management, LLC | 28,704 | $1,641,000 | 1.42% |
Fernwood Investment Management, LLC | 27,550 | $1,575,000 | 0.84% |
Rhenman & Partners Asset Management AB | 100,000 | $5,717,000 | 0.77% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 760,116 | $43,456,000 | 0.65% |
Eventide Asset Management | 214,000 | $12,234,000 | 0.64% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 262,984 | $15,035,000 | 0.59% |
CAPITAL GUARDIAN TRUST CO | 663,089 | $37,909,000 | 0.54% |